The global human microbiome therapeutics market is estimated to grow at a CAGR of 80.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1.6bn in 2025.

How this report will benefit you
  • Read on to discover how you can exploit the future business opportunities emerging in this sector.
  • In this brand new 345-page report you will receive 150 tables and 78 figures– all unavailable elsewhere.
  • The 345-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope

Global Human Microbiome Therapeutics Market forecast from 2020-2030
  • Global Human Microbiome Therapeutics Market revenue forecast 2020-2030 by Sector:
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Metabolic Diseases
  • Dermatological Conditions
  • Other Disorders
Global Human Microbiome Therapeutics Market revenue forecast 2020-2030 by Region:
  • U.S.
  • EU5: Germany, France, U.K., Italy, Spain
  • APAC: Japan, China, India, Australia, Korea
  • Rest of the World

Global Human Microbiome Therapeutics Market Forecast 2020-2030

The human microbiome market revenue forecast 2019-2029 for the US, EU5 and APAC markets are further broken down by sector.


This report discusses the top 20 companies in the human microbiome therapeutics market:
  • 4D Pharma
  • AOBiome Therapeutics
  • C3J Therapeutics
  • Caelus Health
  • Enterome Bioscience
  • Ferring Pharmaceuticals
  • Finch Therapeutics/Crestovo
  • IGEN BIOTECH GROUP
  • Immuron
  • Intrexon Corporation
  • MaaT Pharma
  • MatriSys Biosystem
  • Microbiome Therapeutics LLC
  • Osel
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • Synthetic Biologics
Vedanta Biosciences

This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products

This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.

Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.

Key Questions Answered by this Report:
  • How is the market for human microbiome therapeutics evolving?
  • What is driving and restraining the human microbiome therapeutics market dynamics?
  • What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
  • How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2020 to 2030?
  • Which submarkets will be the main driver of growth in the overall market from 2020 to 2030?
  • How will the regional market shares in the human microbiome therapeutics market change by 2030 and which geographical region will lead the market in 2030?